Cardiotoxicity Profile of Trastuzumab
Authors:
- 1 January 2008
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 31 (6) , 459-467
Abstract
Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor tyrosine kinase HER2/ErbB2. This agent has shown a highly significant antitumour effect for patients with...Keywords
This publication has 23 references indexed in Scilit:
- Reversibility of Trastuzumab Cardiotoxicity: Is the Concept Alive and Well?Journal of Clinical Oncology, 2007
- Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: A systematic reviewEuropean Journal of Cancer, 2007
- 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicityEuropean Journal of Cancer, 2007
- Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of ReversibilityJournal of Clinical Oncology, 2007
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New EntityJournal of Clinical Oncology, 2005
- Cardiac Dysfunction in the Trastuzumab Clinical Trials ExperienceJournal of Clinical Oncology, 2002
- Stimulation of the p38 Mitogen-activated Protein Kinase Pathway in Neonatal Rat Ventricular Myocytes by the G Protein–coupled Receptor Agonists, Endothelin-1 and Phenylephrine: A Role in Cardiac Myocyte Hypertrophy?Journal of Cell Biology, 1998
- Neuregulins Promote Survival and Growth of Cardiac MyocytesJournal of Biological Chemistry, 1998